Impact of Elotuzumab on Multiple Myeloma Patients

The ELOQUENT-3 trial looks at how the of addition of elotuzumab to pomalidomide and dexamethasone impacts patient outcomes in multiple myeloma.  

Source: CancerNetwork - November 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news